Pharma Mar (PHMMF) Projected to Release Earnings on Wednesday

Pharma Mar (OTCMKTS:PHMMF) is expected to be posting its resultson Wednesday, July 29th. Analysts expect Pharma Mar to post earnings of $0.2027 per share and revenue of $51.0340 million for the quarter.

Pharma Mar Stock Performance

Shares of PHMMF opened at $86.09 on Tuesday. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14. Pharma Mar has a one year low of $77.41 and a one year high of $110.40. The business has a fifty day moving average of $91.57 and a 200 day moving average of $93.89.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Zacks Research raised Pharma Mar to a “hold” rating in a research report on Monday, June 15th. BTIG Research assumed coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They set a “buy” rating for the company. Finally, Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.